Targeted next generation sequencing and family survey enable correct genetic diagnosis in CRX associated macular dystrophy - a case report.


Journal

BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802

Informations de publication

Date de publication:
09 Apr 2021
Historique:
received: 24 06 2019
accepted: 23 03 2021
entrez: 10 4 2021
pubmed: 11 4 2021
medline: 15 5 2021
Statut: epublish

Résumé

We present 3 members of a family with macular dystrophy, originally diagnosed as Stargardt disease, with a significantly variable age at onset, caused by a heterozygous mutation in CRX. A 43-year-old female with bull's eye maculopathy, whose sister was diagnosed with Stargardt disease previously at another centre, was found to have a single ABCA4 variant. Further examination of the family revealed that the asymptomatic father was also affected, indicating a dominant pattern of inheritance. In addition, the ABCA4 variant was not identified in the sister originally diagnosed with Stargardt disease. Next generation sequencing identified a heterozygous c.121C > T, p.R41W missense mutation in CRX in all 3 affected members. We describe a common phenotype, but with variable age at onset, with autosomal dominant inheritance and reduced penetrance in a family found to have a pathogenic sequence variant in CRX. This illustrates the importance of panel based molecular genetic testing accompanied by family studies to establish a definitive diagnosis.

Sections du résumé

BACKGROUND BACKGROUND
We present 3 members of a family with macular dystrophy, originally diagnosed as Stargardt disease, with a significantly variable age at onset, caused by a heterozygous mutation in CRX.
CASE PRESENTATION METHODS
A 43-year-old female with bull's eye maculopathy, whose sister was diagnosed with Stargardt disease previously at another centre, was found to have a single ABCA4 variant. Further examination of the family revealed that the asymptomatic father was also affected, indicating a dominant pattern of inheritance. In addition, the ABCA4 variant was not identified in the sister originally diagnosed with Stargardt disease. Next generation sequencing identified a heterozygous c.121C > T, p.R41W missense mutation in CRX in all 3 affected members.
CONCLUSIONS CONCLUSIONS
We describe a common phenotype, but with variable age at onset, with autosomal dominant inheritance and reduced penetrance in a family found to have a pathogenic sequence variant in CRX. This illustrates the importance of panel based molecular genetic testing accompanied by family studies to establish a definitive diagnosis.

Identifiants

pubmed: 33836713
doi: 10.1186/s12886-021-01919-1
pii: 10.1186/s12886-021-01919-1
pmc: PMC8034119
doi:

Substances chimiques

ABCA4 protein, human 0
ATP-Binding Cassette Transporters 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

168

Subventions

Organisme : NIHR Clinical Research Network Thames Valley and South Midlands (GB)
ID : NA

Références

Doc Ophthalmol. 2019 Aug;139(1):45-57
pubmed: 30945053
Arch Ophthalmol. 2012 Nov;130(11):1486-90
pubmed: 23143460
Invest Ophthalmol Vis Sci. 2014 Sep 30;55(10):6934-44
pubmed: 25270190
Genet Med. 2019 Oct;21(10):2336-2344
pubmed: 30926958
Neuron. 1997 Dec;19(6):1329-36
pubmed: 9427255
Science. 1997 Sep 19;277(5333):1805-7
pubmed: 9295268
Br J Ophthalmol. 2007 Dec;91(12):1650-5
pubmed: 18024811
Ophthalmic Genet. 2018 Oct;39(5):637-641
pubmed: 30067412
Invest Ophthalmol Vis Sci. 2011 Oct 31;52(11):8479-87
pubmed: 21911583
Eur J Hum Genet. 2013 Mar;21(3):274-80
pubmed: 22968130
Br J Ophthalmol. 2008 Aug;92(8):1086-91
pubmed: 18653602
Genet Med. 2015 Apr;17(4):262-70
pubmed: 25474345
Int J Mol Sci. 2019 Sep 30;20(19):
pubmed: 31574917
Clin Exp Ophthalmol. 2020 Jul;48(5):644-657
pubmed: 32112665
Cell. 1997 Nov 14;91(4):543-53
pubmed: 9390563
Neuron. 1997 Nov;19(5):1017-30
pubmed: 9390516
Ophthalmic Genet. 2019 Jun;40(3):259-266
pubmed: 31215831
Am J Hum Genet. 1998 Nov;63(5):1307-15
pubmed: 9792858

Auteurs

Saoud Al-Khuzaei (S)

Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Oxford Eye Hospital, John Radcliffe Hospital, Headley Way, Oxford, OX9 3DU, UK.

Karl A Z Hudspith (KAZ)

Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Suzanne Broadgate (S)

Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Morag E Shanks (ME)

Oxford Medical Genetics Laboratory, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Penny Clouston (P)

Oxford Medical Genetics Laboratory, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Andrea H Németh (AH)

Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Stephanie Halford (S)

Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Susan M Downes (SM)

Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. susan.downes@eye.ox.ac.uk.
Oxford Eye Hospital, John Radcliffe Hospital, Headley Way, Oxford, OX9 3DU, UK. susan.downes@eye.ox.ac.uk.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH